FVIII-INHIBITOR-ASSAY

European patent · EP4296681 · In force

Register entry

Publication number
EP4296681
Application number
EP22180750
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Jun 23, 2022
Published
Dec 27, 2023
Granted
Sep 4, 2024
Protection ends at the latest
Jun 22, 2042
Next annual fee due
Jun 30, 2027
IPC classes
G01N 33/86 (2006.01)
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Jul 1, 2026

    Next annual fee due on

    Next annual fee due on
    30.06.2026 → 30.06.2027

    Published in Swissreg on 01.07.2026

  2. Jul 16, 2025

    Change

    Published in Swissreg on 16.07.2025

  3. Jul 1, 2025

    Next annual fee due on

    Next annual fee due on
    30.06.2025 → 30.06.2026

    Published in Swissreg on 01.07.2025

  4. Oct 31, 2024

    Agent entered

    Representative
    Murgitroyd & Company, Geneva Rhone 8 Sàrl, Rue du Commerce 4, 1204 Genève

    Published in Swissreg on 31.10.2024

  5. Sep 4, 2024

    Granted

    Published in Swissreg on 04.09.2024

Parties

Holder

Technoclone Herstellung von Diagnostika und Arzneimitteln GmbH

Brunner Straße 67, 1230 Vienna, AT

Agent

Murgitroyd & Company

Geneva Rhone 8 Sàrl Rue du Commerce 4, 1204 Genève

Inventor

Verbruggen, Hubertus Wilhelmus

6525EG Nijmegen, NL

Binder, Nikolaus

1230 Vienna, AT

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.